Eli Lilly's tender offer for Adverum Biotechnologies is entering its final stretch, with the Redwood City gene therapy house issuing a formal reminder to stockholders. The $10.00-per-share all-cash bid, announced in October, values the clinical-stage company at roughly $836 million on a fully diluted basis. Adverum trades on Nasdaq under ADVM, and the tender window closes December 13 unless extended.
Adverum's core asset is an intravitreal gene therapy platform targeting retinal diseases. The company holds clinical programs in wet age-related macular degeneration and diabetic macular edema, both large indications with existing anti-VEGF treatment regimes that require frequent injections. Lilly's interest centers on the potential for durable, single-administration therapies that collapse chronic treatment burdens into one-time interventions. The deal includes Adverum's manufacturing capabilities in Redwood City and a clinical data package spanning multiple Phase 2 readouts.
The tender reminder arrives as Lilly continues to build out its ophthalmology portfolio alongside its dominance in diabetes and obesity. The company reported $11.4 billion in third-quarter revenue, driven by Mounjaro and Zepbound, and has earmarked ophthalmology as a strategic adjacency where diabetes co-morbidities create natural patient overlap. Adverum's platform, if validated in late-stage trials, would allow Lilly to own the transition from chronic injections to gene therapy in a $15 billion global retinal disease market.
The timing of the reminder is standard procedure but signals Lilly's intent to close without friction. Tender offers typically include multiple stockholder communications as deadlines approach, and this notice follows a standard playbook for ensuring high acceptance rates. Adverum's board has already recommended the offer unanimously, and no competing bids have emerged since the announcement. The absence of a go-shop provision suggests Lilly negotiated exclusivity early, and the $10.00 price represents a 90% premium to Adverum's pre-announcement trading level.
Operators should monitor the tender acceptance rate, which Lilly will disclose within two business days of the December 13 deadline. A sub-90% acceptance would be unusual given board backing, but any material shortfall could trigger extension or pricing adjustments. Separately, Adverum's Phase 2b data in wet AMD, expected in early 2026, will either validate or challenge Lilly's thesis. The company's lead candidate, ADVM-022, delivered mixed durability signals in earlier cohorts, and Lilly is betting its process improvements solve the transience problem.
The deal closes a chapter for Adverum, which burned through $400 million in cumulative R&D since its 2014 founding without reaching pivotal trials. Lilly acquires the platform, the talent, and the optionality to pivot should early bets falter. The stockholders tendering now exit at a fixed price. The ones who decline will hold equity in a Lilly subsidiary with no public liquidity and diminishing governance rights. December 13 is the last date that distinction matters.